Le Lézard
Classified in: Health, Business
Subject: JVN

RaySearch and Vision RT Announce Strategic Partnership


STOCKHOLM, July 14, 2019 /PRNewswire/ -- While details of these developments are currently confidential, both companies' intention is to deliver both improved integration and entirely new capabilities to radiation oncology professionals, to help enhance workflow and improve clinical decision-making.

Vision RT and RaySearch make natural partners as their activities are very complementary, while they are both highly focused on innovative customers looking to deliver high quality care in the radiation oncology space.

Norman Smith, founder and CEO of Vision RT, says: "RaySearch continue to develop highly valuable and innovative technologies within the radiation oncology space. We are delighted to be entering a partnership with RaySearch, during which we will be developing interfaces to ensure seamless workflows between our respective products and collaborating with joint customers to further enhance their user experience."

Johan Löf, founder and CEO of RaySearch, says: "I believe that the combination of Vision RT sensor technologies and the software capabilities of RayStation, RayCare and RayCommand has great potential."

About Vision RT
Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with products installed in many of the leading treatment centers in the world, including around 70% of the 50 US News "Best Hospitals for Cancer". With 70 granted patents plus 51 pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide. Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation®* treatment planning system and RayCare®*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch's software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayCare
RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow's requirements for advanced analytics and decision support in mind.

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

More information about RaySearch is available at www.raysearchlabs.com. 

* Subject to regulatory clearance in some markets.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/raysearch-and-vision-rt-announce-strategic-partnership,c2861854

The following files are available for download:

https://mb.cision.com/Main/1102/2861854/1076374.pdf

Release

https://news.cision.com/raysearch-laboratories/i/visionrt-pr-1200x620,c2654575

Visionrt PR 1200x620

 

For further information, please contact:

Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510-530-00
johan.lof@raysearchlabs.com 

Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70-661-05-59
peter.thysell@raysearchlabs.com 

 

SOURCE RaySearch Laboratories


These press releases may also interest you

at 14:08
Jennifer Aviado-Langer, DNP, FNP is recognized by Continental Who's Who for her outstanding contributions in the medical field as a Doctor of Nursing Practice and Family Nurse Practitioner at Memorial Sloan Kettering Cancer Center.            ...

at 14:08
Richard J. Juda, MD, MBA, CPE is recognized by Continental Who's Who as a Prominent Lifetime Achiever in the field of Medical Management for his role as CEO of Innovative Healthcare Group.           Dr. Juda has been serving the Hospital Management...

at 14:00
A new pilot study recently published in CDN (Current Developments In Nutrition) concluded that Pediococcus acidilactici NRRL B-50517 (PA-5051) is a safe probiotic for human consumption and may be useful in reducing body fat and pro-inflammatory...

at 13:50
States with stricter firearms laws had lower firearm-related deaths among children and adolescents, finds research led by faculty at Children's National in Washington, D.C. Furthermore, state laws that had been in place for more than five years...

at 13:42
The style of tackling used in rugby may be associated with a lower force of impact than the style used in football, according to a preliminary study of college athletes released today that will be presented at the American Academy of Neurology Sports...

at 13:36
Hematogenix®, a global leader in the field of cancer research and immuno-oncology testing, announces the availability of the assessment of B-cell maturation antigen (BCMA) by flow cytometry and immunohistochemistry (IHC) at its facilities globally....



News published on 14 july 2019 at 10:27 and distributed by: